THE JOURNAL OF CLINICAL PSYCHIATRY

Supplementary Material

Article Title: Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres: A Randomized Controlled Trial

Author(s): Nancy H. Covell, PhD; Joseph P. McEvoy, MD; Nina R. Schooler, PhD; T. Scott Stroup, MD, MPH; Carlos T. Jackson, PhD; Ingrid A. Rojas, MPH; and Susan M. Essock, PhD; for the Schizophrenia Trials Network

Citation: J Clin Psychiatry 2012;73

DOI Number: 10.4088/JCP.11m07074

List of Supplementary Material for the article

1. eFigure 1 — Recruitment Flow for Effectiveness of Switching: Injectable to Injectable
2. eTable 1 — Intent to Treat Means of Secondary Outcome Measures Through Time for People with Schizophrenia-Spectrum Disorders in a Randomized Controlled Study of Staying on a First Generation Antipsychotic Injectable versus Switching to Long-Acting Injectable Risperidone Microspheres

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eFigure 1. Recruitment Flow for Effectiveness of Switching: Injectable to Injectable



© Copyright 2012 Physicians Postgraduate Press, Inc.

Supplementary eTable 1. Intent to Treat Means of Secondary Outcome Measures Through Time for People with Schizophrenia-Spectrum Disorders in a Randomized Controlled Study of Staying on a First Generation Antipsychotic Injectable versus Switching to Long-Acting Injectable Risperidone Microspheres

	Randomly Assigned to Stay on First Generation Injectable (N=30)			**Randomly Assigned to Stay on Fluphenazine Decanoate** (N=11)			**Randomly Assigned to Stay on Haloperidol Decanoate** (N=19)			**Randomly Assigned to Switch to Long-Acting Injectable Risperidone Microspheres** (N=32)		
PANSS Total Score												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	30	69.9	17.9	11	65.8	18.2	19	72.2	17.8	32	65.4	14.0
2 Weeks	26	65.8	17.9	10	68.2	20.1	16	64.3	16.9	21	67.7	14.5
1 Month	27	64.4	17.5	9	67.0	19.6	18	63.2	16.8	24	66.8	13.2
3 Months	26	62.4	17.8	9	60.0	17.8	17	63.8	18.3	23	63.1	13.6
6 Months	24	61.0	19.3	9	58.6	19.3	15	62.5	19.8	22	60.9	10.7
9 Months	26	64.2	16.3	9	64.6	18.7	17	64.1	15.5	17	57.9	10.5
12 Months	25	62.2	20.0	9	67.6	24.2	16	59.3	17.2	18	64.0	19.2
Proportion of those without evidence of Tardive Diskinesia at baseline												

who had evidence of Tardive Dyskinesia at follow-up												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	21	0	0	8	0	0	13	0	0	19	0	0
2 Weeks	19	.11	0.3	8	.13	0.4	11	.09	0.3	11	.18	0.4
1 Month	19	.00	0.0	7	.00	0.0	12	.00	0.0	14	.14	0.4
3 Months	19	.00	0.0	7	.00	0.0	12	.00	0.0	12	.17	0.4
6 Months	18	.17	0.4	7	.29	0.5	11	.09	0.3	12	.25	0.5
9 Months	19	.16	0.4	7	.14	0.4	12	.17	0.4	9	.11	0.3
12 Months	18	.06	0.2	7	.00	0.0	11	.09	0.3	10	.50	0.5

Proportion of those without evidence of EPS at baseline who had evidence of EPS at follow-up												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	22	0	0	9	0	0	13	0	0	18	0	0
2 Weeks	19	.05	0.2	8	.13	0.4	11	.00	0.0	10	.10	0.3
1 Month	19	.05	0.2	7	.00	0.0	12	.08	0.3	12	.00	0.0
3 Months	19	.05	0.2	7	.00	0.0	12	.08	0.3	11	.09	0.3
6 Months	18	.06	0.2	7	.00	0.0	11	.09	0.3	11	.09	0.3
9 Months	19	.16	0.4	7	.14	0.4	12	.17	0.4	8	.13	0.4
12 Months	18	.17	0.4	7	.14	0.4	11	.18	0.4	9	.11	0.3

Change in Body Mass Index												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	30	0	0	11	0	0	19	0	0	32	0	0
2 Weeks	26	.10	1.0	10	-.12	1.2	16	.24	0.8	21	.20	1.1
1 Month	27	.39	1.0	9	.20	1.0	18	.49	0.9	23	.40	1.2
3 Months	26	.48	1.4	9	.00	1.0	17	.73	1.6	23	1.29	1.9
6 Months	24	.53	1.3	9	.48	1.0	15	.56	1.4	22	1.53	2.2
9 Months	25	.16	1.3	9	.36	0.9	16	.05	1.5	17	1.38	2.4
12 Months	24	-.28	1.7	9	.09	1.3	15	-.50	1.9	17	1.04	2.0

Arizona Sexual Experiences Scale Total												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	27	15.2	5.0	10	17.0	5.1	17	14.2	4.7	29	15.9	5.6
2 Weeks	23	15.9	5.7	8	16.5	4.3	15	15.5	6.4	19	16.6	5.7
1 Month	23	15.7	6.2	7	16.6	6.6	16	15.4	6.2	21	17.7	4.1
3 Months	24	14.9	5.1	7	15.7	5.4	17	14.5	5.1	20	16.6	4.9
6 Months	23	15.4	5.2	8	16.4	5.4	15	14.9	5.2	18	16.7	6.3
9 Months	23	15.4	6.6	8	16.0	7.3	15	15.1	6.4	15	16.7	5.3
12 Months	24	17.0	7.1	8	17.6	6.9	16	16.7	7.5	16	16.9	5.7

Prolactin (ng/ml) – All Study Participants												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	23	18.5	13.8	7	19.3	12.4	16	18.2	14.7	26	16.7	9.8
2 Weeks	20	14.1	6.6	7	12.9	3.5	13	14.7	7.9	17	17.1	18.1
1 Month	22	16.4	10.1	8	14.9	5.2	14	17.2	12.2	21	21.1	19.6

3 Months	22	15.1	7.6	8	13.1	5.8	14	16.2	8.5	19	22.5	19.1
6 Months	21	16.0	7.5	9	16.7	8.9	12	15.5	6.6	18	23.4	13.8
9 Months	18	16.2	8.0	7	12.6	2.8	11	18.5	9.4	15	19.5	12.1
12 Months	18	15.2	5.1	7	16.1	6.3	11	14.7	4.4	14	19.0	10.6
Prolactin (ng/ml) – Women only												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	5	26.9	22.7	2	29.1	22.2	3	25.4	28.0	8	23.6	11.3
2 Weeks	4	18.0	11.5	1	16.5	--	3	18.5	14.1	5	34.6	25.9
1 Month	5	21.3	16.1	2	15.7	4.0	3	25.0	21.4	5	34.8	32.5
3 Months	6	14.6	6.9	2	13.0	6.1	4	15.4	8.0	5	36.7	29.3
6 Months	7	15.4	10.5	3	21.2	14.7	4	11.1	4.6	4	38.9	19.1
9 Months	6	12.4	5.6	2	11.7	4.3	4	12.8	6.8	2	33.1	5.5
12 Months	6	16.5	6.9	3	19.0	7.3	3	14.0	7.0	3	23.1	14.5
Prolactin (ng/ml) – Men only												
	N	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**	**N**	**Mean**	**SD**
Baseline	18	16.2	9.9	5	15.3	6.4	13	16.5	11.2	18	13.6	7.6
2 Weeks	16	13.1	4.9	6	12.3	3.4	10	13.6	5.8	13	10.3	5.9
1 Month	17	14.9	7.7	6	14.6	5.8	11	15.1	8.8	16	16.8	12.2
3 Months	16	15.2	8.1	6	13.1	6.3	10	16.5	9.1	14	17.5	11.6
6 Months	14	16.3	5.9	6	14.5	4.8	8	17.7	6.6	14	19.0	8.3
9 Months	12	18.1	8.5	5	12.9	2.6	7	21.8	9.5	13	17.4	11.5
12 Months	12	14.6	4.2	4	14.0	5.6	8	14.9	3.7	11	17.9	9.9